These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19900396)

  • 21. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
    Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
    Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines.
    Mayfield S; Vaughn JP; Kute TE
    Breast Cancer Res Treat; 2001 Nov; 70(2):123-9. PubMed ID: 11768602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Killing effect of Photofrin-Herceptin immunoconjugate on tumor cell lines in vitro].
    Qian XY; Luo RC; Li LB; Liao WJ; Luo YL
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Aug; 25(8):975-8. PubMed ID: 16109553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probing different perfluorocarbons for in vivo inflammation imaging by 19F MRI: image reconstruction, biological half-lives and sensitivity.
    Jacoby C; Temme S; Mayenfels F; Benoit N; Krafft MP; Schubert R; Schrader J; Flögel U
    NMR Biomed; 2014 Mar; 27(3):261-71. PubMed ID: 24353148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Killing effect of sequential Herceptin and adriamycin treatment on breast cancer cell line in vitro].
    Tan K; Fan YX; Miao JX; Lü CW; Yan X; Luo RC
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):234-6. PubMed ID: 16503541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [188Re-labeled herceptin inhibits proliferation of breast cancer cell line SKBR-3 in vitro].
    Li GP; Zhang YF; Wang YX
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Oct; 26(10):1455-7. PubMed ID: 17062351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Herceptin-platinum(II) binding complexes: novel cancer-cell-specific agents.
    Gao J; Liu YG; Liu R; Zingaro RA
    ChemMedChem; 2008 Jun; 3(6):954-62. PubMed ID: 18366039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
    Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
    Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of HER-2/neu in uterine serous papillary cancer.
    Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
    Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
    Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S
    J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
    McKenzie T; Liu Y; Fanale M; Swisher SG; Chada S; Hunt KK
    Surgery; 2004 Aug; 136(2):437-42. PubMed ID: 15300212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
    Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
    Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability.
    Kang SH; Kang KW; Kim KH; Kwon B; Kim SK; Lee HY; Kong SY; Lee ES; Jang SG; Yoo BC
    BMC Cancer; 2008 Oct; 8():286. PubMed ID: 18834540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A chemical shift encoding (CSE) approach for spectral selection in fluorine-19 MRI.
    Ludwig KD; Hernando D; Roberts NT; van Heeswijk RB; Fain SB
    Magn Reson Med; 2018 Apr; 79(4):2183-2189. PubMed ID: 28833448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cargo-influences on the biodistribution of hollow mesoporous silica nanoparticles as studied by quantitative
    Pochert A; Vernikouskaya I; Pascher F; Rasche V; Lindén M
    J Colloid Interface Sci; 2017 Feb; 488():1-9. PubMed ID: 27816633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.